Microbial and viral structural proteins

Microbial and viral structural proteins are essential components that form the physical architecture of pathogens, including the capsids and envelopes of viruses and the surface layers of bacteria (NCBI Bookshelf, 2021). These proteins play critical roles in protecting the pathogen's genetic material from environmental degradation and host immune factors (Lodish et al., 2000). Beyond structural integrity, they facilitate the initial stages of infection by mediating attachment to specific host cell receptors and promoting the fusion of viral and cellular membranes (Nature Reviews Microbiology, 2019). In clinical medicine, these proteins are the primary targets for vaccine development, as they are often the most exposed antigens for neutralizing antibody recognition (Science, 2021). Therapeutic agents such as fusion inhibitors and monoclonal antibodies specifically target these structural entities to block pathogen entry and spread within the host (NEJM, 2003). For instance, drugs like enfuvirtide target the HIV-1 gp41 protein to prevent viral-cell fusion, while various monoclonal antibodies target the SARS-CoV-2 spike protein (Nature, 2020). Because these proteins are pathogen-specific, they offer a high degree of selectivity for drug design, minimizing off-target effects on host cells. However, the high mutation rates observed in many viral structural proteins present a significant challenge, often leading to the rapid emergence of resistant variants (Cell, 2022).

Other names

Pathogen structural proteinsViral capsid proteinsViral envelope proteinsBacterial surface proteinsSurface antigens

Drugs targeting these proteins primarily act by inhibiting viral entry, preventing the fusion of viral and host membranes, neutralizing surface antigens to block receptor binding, or disrupting the assembly and stability of the pathogen's structural framework (Nature Reviews Microbiology, 2019; NEJM, 2003).